News

Article

HS-20093 Generates Responses in Pretreated ES-SCLC

Author(s):

Fact checked by:

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

HS-20093 in Pretreated ES-SCLC | Image Credit: © vitanovski - stock.adobe.com

Lung Cancer | Image Credit:

© Axel Kock - stock.adobe.com

Treatment with the novel B7-H3–targeted antibody-drug conjugate (ADC) HS-20093 led to responses in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to data from the phase 1 ARTEMIS-001 trial (NCT05276609) presented at the 2024 IASLC World Conference on Lung Cancer.

Findings showed that patients treated with HS-20093 at 8 mg/kg once every 3 weeks (n =31) achieved an overall response rate (ORR) of 61.3% (95% CI, 42.2%-78.2%). Those treated with the ADC at 10 mg/kg once every 3 weeks (n = 22) experienced an ORR of 50.0% (95% CI, 28.2%-71.8%). The disease control rate (DCR) was 80.6% (95% CI, 62.5%-92.5%) for the 8.0-mg/kg cohort and 95.5% (95% CI, 77.2%-99.9%) for the 10.0-mg/kg cohort.

“HS-20093 demonstrated encouraging antitumor efficacy in ES-SCLC and has a higher ORR [at] the 8.0-mg/kg dose, even though this dose [cohort] had [a higher proportion of patients] with brain, liver, and bone metastases,” lead study author Jie Wang, MD, PhD, of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, China, said in a presentation of the data.

HS-20093 features a fully humanized anti–B7-H3 monoclonal antibody that is linked via a cleavable maleimide tetrapeptide linker to a topoisomerase I inhibitor that is a derivative of exatecan.

The Investigation of HS-20093 in ARTEMIS-001

ARTEMIS-001 was a multicenter, open-label trial that evaluated HS-20093 is patients with advanced solid tumors. To enroll, patients with ES-SCLC were required to have received previous treatment with platinum-based chemotherapy with or without prior immunotherapy. No more than 3 prior lines of therapy were permitted. Patients with treated or stable brain metastases were allowed to enroll. Patients were unselected for B7-H3 expression.

During dose escalation in phase 1a, patients received HS-20093 at 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg, 6.0 mg/kg, 8.0 mg/kg, 12.0 mg/kg, or 16.0 mg/kg. In dose expansion during phase 1b, patients with ES-SCLC were randomly assigned 1:1 to receive the ADC at 8.0 mg/kg or 10.0 mg/kg once every 3 weeks.

Investigator-assessed ORR per RECIST 1.1 criteria served as the trial’s primary end point. Secondary end points included safety, pharmacokinetics, duration of response (DOR), DCR, progression-free survival (PFS) per RECIST 1.1 criteria, and overall survival (OS).

Among 56 patients with ES-SCLC who were treated with HS-20093, 53 were evaluable for efficacy. Among all patients treated at 8.0 mg/kg (n = 31) or 10 mg/kg (n = 25), the median age was 57.0 years (range, 30-74), and 76.8% of patients were male. The mean body weight was 64.02 kg (standard deviation, 10.482). Patients had an ECOG performance status of 0 (12.5%) or 1 (87.5%). Additionally, at baseline, 14.3% of patients had brain metastases, 46.4% had liver metastases, and 28.6% had bone metastases.

Patients had received a median of 2.0 prior lines of systemic therapy (range, 1-6). Prior therapies included etoposide plus platinum-based chemotherapy (100%), immunotherapy (73.2%), and a topoisomerase I inhibitor (23.2%).

Additional Efficacy and Safety Data

The median DOR was 6.4 months (95% CI, 4.2-12.7) in the 8.0-mg/kg cohort and 8.9 months (95% CI, 2.7–not applicable [NA]) in the 10.0-mg/kg cohort.

Patients in the 8.0-mg/kg cohort achieved a median PFS of 5.9 months (95% CI, 4.4-8.5), and those in the 10.0-mg/kg cohort experienced a median PFS of 7.3 months (95% CI, 3.4-11.0).

The median OS was 9.8 months (95% CI, 8.5-NA) and not reached in the 8.0-mg/kg and 10.0-mg/kg groups, respectively.

Notably, patients in the 8.0-mg/kg cohort who had received prior treatment with platinum-based chemotherapy and immunotherapy but were naive to a topoisomerase I inhibitor (n = 20) experienced an ORR of 75.0% (95% CI, 50.9%-91.3%). Patients in this subgroup treated with HS-20093 at 10.0 mg/kg (n =12) achieved an ORR of 66.7% (95% CI, 34.9%-90.1%).

Among patients with platinum-resistant disease (n = 28)—defined as a platinum-free interval of less than 90 days—the ORR was 57.1% (95% CI, 37.2%-75.5%). Those with platinum-sensitive disease (n = 18)—defined as a platinum-free interval of at least 90 days—experienced an ORR of 61.1% (95% CI, 35.7%-82.7%).

Regarding safety, the most common treatment-related adverse effects (AEs) reported in at least 20% of patients included anemia (any-grade, 85.7%; grade ≥ 3, 16.1%), decreased white blood cell count (80.4%; 33.9%), decreased neutrophil count (67.9%; 39.3%), decreased platelet count (53.6%; 17.9%), nausea (51.8%; 5.4%), pyrexia (48.2%; 0%), decreased appetite (42.9%; 1.8%), increased alanine aminotransferase (39.3%; 1.8%), increased aspartate aminotransferase (39.3%; 3.6%), asthenia (39.3%; 5.4%), vomiting (39.3%; 7.1%), decreased lymphocyte count (32.1%; 25.0%), hypoalbuminemia (30.4%; 0%), decreased weight (23.2%; 1.8%), and hyponatremia (21.4%; 0%).

“Compared with the 10.0-mg/kg [dose], the 8.0-mg/kg [dose] had a better safety profile in terms of hematologic AEs. No new safety signals were identified,” Wang said.

B7-H3 Biomarker Analysis

In the 8.0-mg/kg cohort, evaluable patients who had a B7-H3 expression of less than 1% (n = 8) experienced an ORR of 75.0% (95% CI, 34.9%-96.8%). Those with a B7-H3 expression of 1% to 100% (n = 21) had an ORR of 61.9% (95% CI, 38.4%-81.9%; P = .67).

In the 10.0-mg/kg cohort, patients with a B7-H3 expression of less than 1% (n = 7) had an ORR of 71.4% (95% CI, 29.0%-96.3%). Patients with a B7-H3 expression of 1% to 100% (n = 14) had an ORR of 42.9% (95% CI, 17.7%-71.1%; P = .36).

“A low correlation was observed between tumor B7-H3 expression and tumor objective response,” Wang concluded.

Reference

Wang J, Duan J, Wu L, et al. Efficacy and safety of HS-20093 in extensive stage small cell lung cancer in a multicenter, phase 1 study (ARTEMIS-001). Presented at: 2024 IASLC World Conference on Lung Cancer; September 6-10, 2024; San Diego, CA. Abstract OA04.06.

Related Videos
Sally Lau, MD
Andrea Wolf, MD, MPH
Jacob Sands, MD
Marina Chiara Garassino, MD
Nicolas Girard, MD
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Nicolas Girard, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO